Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial

Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial

Item

http://www.wikidata.org/entity/Q57904482

Q57904482

about

Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies.Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer.Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Co Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes.Evaluation of two highly-multiplexed custom panels for massively parallel semiconductor sequencing on paraffin DNA Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts.Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials.Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group.Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials.Protein expression patterns of cell cycle regulators in operable breast cancer.Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy.Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer.Survival from breast cancer in relation to access to tertiary healthcare, body mass index, tumor characteristics and treatment: a Hellenic Cooperative Oncology Group (HeCOG) study.A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy

P2860

Q26853619-D5C044D4-3698-4E4B-8DE5-D6154C923CF8 Q27016629-8B1999B1-3623-4D4F-B5D7-5AA77FB06838 Q28728830-6EE443A5-8B3C-44E6-9E41-227CAAC87573 Q33830446-547E4E30-2B9C-4893-84C1-F1C68D117CE8 Q34010867-7E5B6D5A-D52D-44D0-8BA7-C6D7882E4706 Q34071621-47C2138F-89E9-488A-AEEB-F9196731B39B Q34468964-97BE1B74-F1E8-4D7E-8583-13B999DB7E25 Q34640536-13631800-042B-4553-8912-E20FB896C395 Q35123145-1D60ED8C-B2F8-495B-9A3D-320132479794 Q35651423-AE9C43B7-7F0F-4B2C-8DA1-FE9ECA955840 Q35663809-19F3FEAB-06B4-4645-95E2-6DA993B52838 Q35801713-A375B363-0F84-4B62-9B6A-C44CC3735672 Q36151341-1CCB13EC-31B6-46BA-ACCC-C77D17AF6C2B Q36379148-4A865D73-E3F3-46AA-B890-E7D218C6B985 Q36782680-5534E421-6B8C-43E0-AEA7-DACD0697B53C Q37309845-49DFD519-1C25-4793-AAA5-18F977D3141A Q37362747-B582C10D-905E-42B9-AD8A-EDED657E5AC7 Q37638287-1FCF18EE-A7BE-4A46-B6AC-1CA393B6E066 Q38445535-3615015F-8AF5-4503-9972-C7D058B67FA5 Q38630291-3A38417D-CFAB-46C6-B724-FF23E7C1C46E Q38699879-F4B9A8B8-4CEC-447C-95AE-3A6509CF1D58 Q44294451-B2FDD5BC-5A06-498B-A7BC-FAC200C6C78E Q44763826-163D1055-B22E-43DA-B643-2F96D31D92D5 Q50990877-1035D907-5C6C-496B-AE09-DDF8D20A6BA8 Q57152794-506A2084-6DD6-496A-B027-9AEB067CE0FC

P2860

Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial

Item

http://www.wikidata.org/entity/Q57904482

description

im Dezember 2011 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 21 December 2011

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в грудні 2011

@uk

name

Postoperative dose-dense seque ...... Group HE 10/00 phase III Trial

@en

Postoperative dose-dense seque ...... Group HE 10/00 phase III Trial

@nl

type

Item

label

Postoperative dose-dense seque ...... Group HE 10/00 phase III Trial

@en

Postoperative dose-dense seque ...... Group HE 10/00 phase III Trial

@nl

prefLabel

Postoperative dose-dense seque ...... Group HE 10/00 phase III Trial

@en

Postoperative dose-dense seque ...... Group HE 10/00 phase III Trial

@nl

P1476

Postoperative dose-dense seque ...... Group HE 10/00 phase III Trial

@en

P2093

Anna Batistatou

http://www.w3.org/2001/XMLSchema#string

Charisios Karanikiotis

http://www.w3.org/2001/XMLSchema#string

Christos Christodoulou

http://www.w3.org/2001/XMLSchema#string

Christos Papadimitriou

http://www.w3.org/2001/XMLSchema#string

Dimitrios Bafaloukos

http://www.w3.org/2001/XMLSchema#string

Dimitrios Pectasides

http://www.w3.org/2001/XMLSchema#string

Eleni Timotheadou

http://www.w3.org/2001/XMLSchema#string

Epaminontas Samantas

http://www.w3.org/2001/XMLSchema#string

Evangelos Briasoulis

http://www.w3.org/2001/XMLSchema#string

George Fountzilas

http://www.w3.org/2001/XMLSchema#string

P2860

Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.

Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.

Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.

Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Theoretical concepts and the emerging role of taxanes in adjuvant therapy.

Effect of screening and adjuvant therapy on mortality from breast cancer.

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

Selection of adjuvant chemotherapy for treatment of node-positive breast cancer.

P2888

s10549-011-1913-4

P304

609-619

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-011-1913-4

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

132

http://www.w3.org/2001/XMLSchema#string

P50

Mattheos Bobos

Meletios A. Dimopoulos

Urania Dafni

Christos Markopoulos

Anastasia G Eleftheraki

H P Kalofonos

P577

2011-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22187126

http://www.w3.org/2001/XMLSchema#string

P921

patient

Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial

about

P2860

P2860

Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921